Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.

Discussion and conclusion A prognostic model for OS was established and validated. This model can be used by physicians to risk stratify the individual patient and together with the patient decide whether to initiate BEV relapse treatment.
PMID: 26828563 [PubMed - as supplied by publisher]

Source: Acta Oncologica - February 1, 2016 Category: Cancer & Oncology Authors: Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U Tags: Acta Oncol Source Type: research